MINERVA BIOTECHNOLOGY AND BIOMOLECULAR RESEARCH, vol.34, no.2, pp.71-79, 2022 (SCI-Expanded)
BACKGROUND: Developing safe drugs for tuberculosis (TB), is a major challenge due to upsurge in drug resistance, hepatotoxicity, and the presence of Mycobacterium tuberculosis (Mtb) targets orthologs in human and its non-pathogenic host E. coli. Prostaglandin G/H synthase-2 and 30S ribosomal-S12 protein of Mtb show 100 and 48% similarity with human proteins respectively. Thus, targeting these Mtb proteins by p-aminosalicylic acid and streptomycin for the treatment of TB adversely affect human metabolism, and warrants to identify novel and unique drug targets of Mtb.